Surgalign & NuVasive: How they line up in Q1

Medical technology companies Surgalign and NuVasive posted their first quarter financial results for 2023. 

Advertisement

Here is how they compare: 

Surgalign

Revenue: $16.7 million

Operating loss: $1.1 million 

Year-over-year revenue dip: $3.9 million

NuVasive

Sales: $307.7 million

Operating loss: $1 million

Year-over-year sales increase: $17 million

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.